BioAge Labs (NASDAQ:BIOA) Issues Earnings Results, Beats Expectations By $0.07 EPS

BioAge Labs (NASDAQ:BIOA) released its quarterly earnings data on Wednesday. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.07, Zacks reports. The business had revenue of $2.45 million for the quarter. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%.

BioAge Labs Trading Down 2.0%

Shares of BioAge Labs stock opened at $10.98 on Thursday. The company’s 50-day moving average price is $20.27 and its 200-day moving average price is $19.30. BioAge Labs has a 12-month low of $4.25 and a 12-month high of $25.95. The company has a market cap of $488.06 million, a price-to-earnings ratio of -4.57 and a beta of 0.93.

Institutional Trading of BioAge Labs

A number of hedge funds and other institutional investors have recently bought and sold shares of BIOA. Price T Rowe Associates Inc. MD grew its position in BioAge Labs by 24.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,808 shares of the company’s stock worth $196,000 after buying an additional 2,917 shares in the last quarter. MetLife Investment Management LLC purchased a new stake in shares of BioAge Labs in the 4th quarter valued at about $191,000. Great Lakes Advisors LLC bought a new stake in shares of BioAge Labs during the 4th quarter valued at about $214,000. JPMorgan Chase & Co. grew its holdings in shares of BioAge Labs by 228.7% during the third quarter. JPMorgan Chase & Co. now owns 36,848 shares of the company’s stock worth $217,000 after purchasing an additional 25,638 shares in the last quarter. Finally, Militia Capital Partners LP purchased a new position in shares of BioAge Labs during the second quarter worth about $166,000.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. BTIG Research reissued a “buy” rating and issued a $40.00 price target on shares of BioAge Labs in a research report on Monday. Needham & Company LLC cut their price objective on shares of BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a report on Friday, July 31st. Wall Street Zen lowered shares of BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Roth Capital reissued a “buy” rating and set a $25.00 target price on shares of BioAge Labs in a report on Friday, July 31st. Finally, Jefferies Financial Group set a $21.00 target price on BioAge Labs in a research report on Friday, July 31st. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $36.57.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.